Unit­ed Ther­a­peu­tic­s' drug fails PhII/III can­cer tri­al, mark­ing their sec­ond straight stum­ble in post-Re­mod­ulin PAH

Make that 0-for-their-last-2 for Unit­ed Ther­a­peu­tics.

Near­ly a year af­ter a drug can­di­date-killing PAH tri­al fail­ure, Unit­ed an­nounced its Phase II/III tri­al com­bin­ing their Uni­tux­in an­ti­body with a stan­dard treat­ment, irinote­can, failed to help small cell lung can­cer pa­tients live longer.

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER